The results showed that tirzepatide was well-tolerated, with most participants experiencing mild to moderate adverse events such as nasopharyngitis, nausea, constipation, diarrhea, and decreased appetite
On Zepbound or not
Weight-loss drug approved for heart problems in UK Weight-loss treatment Wegovy has been approved by the UK's medicines regulator, for reducing the risk of serious heart problems in overweight and obese people
Participants who were given a higher dose of AOD-9604 (10 mg/day) did not lose more weight
The trial result that drew comparisons to surgery In TRIUMPH-1, Lillys pivotal obesity trial with 2,339 participants, people on the highest dose lost an average of 28.3 percent of their body weight over 80 weeks
doi: 10.1258/0007142991902295 127 HuetODupicLHarroisADuranteauJ